Artelo Biosciences (ARTL) EBT (2014 - 2025)
Artelo Biosciences (ARTL) posted quarterly EBT of -$2.8 million for Q4 2025, up 70.92% year-over-year from -$1.6 million in Q4 2024, and up 13.62% quarter-over-quarter from -$3.2 million in Q3 2025.
Artelo Biosciences (ARTL) EBT (2014 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported EBT for 12 consecutive years, with -$2.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, EBT rose 70.92% year-over-year to -$2.8 million; the TTM figure through Dec 2025 stood at -$12.0 million (up 24.13% YoY), while the FY2025 annual figure was -$19.2 million, down 21.76% from the prior year.
- EBT rose to -$2.8 million in Q4 2025 per ARTL's latest filing, from -$3.2 million in the prior quarter.
- Across five years, EBT topped out at -$1.2 million in Q3 2024 and bottomed at -$9.5 million in Q4 2024.
- Historically, EBT has averaged -$2.9 million across 5 years, with a median of -$2.5 million in 2021.
- Annual changes were most pronounced in 2024 — EBT sank 192.9% — and 2025, when it surged 70.92%.
- Artelo Biosciences' EBT stood at -$2.6 million in 2021, then plunged by 36.06% to -$3.5 million in 2022, then gained by 6.66% to -$3.2 million in 2023, then tumbled by 192.9% to -$9.5 million in 2024, then soared by 70.92% to -$2.8 million in 2025.
- Business Quant data shows ARTL's EBT at -$2.8 million in Q4 2025, -$3.2 million in Q3 2025, and -$3.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 81.49 Mn |
| 10 | Artelo Biosciences | 113,239.32 | -486,760.68 | - | -2.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.76 Mn |
| Sep 30, 2025 | -3.20 Mn |
| Jun 30, 2025 | -3.68 Mn |
| Mar 31, 2025 | -2.38 Mn |
| Dec 31, 2024 | -9.49 Mn |
| Sep 30, 2024 | -1.20 Mn |
| Jun 30, 2024 | -2.53 Mn |
| Mar 31, 2024 | -2.61 Mn |
| Dec 31, 2023 | -3.24 Mn |
| Sep 30, 2023 | -2.65 Mn |
| Jun 30, 2023 | -1.81 Mn |
| Mar 31, 2023 | -2.30 Mn |
| Dec 31, 2022 | -3.47 Mn |
| Sep 30, 2022 | -2.40 Mn |
| Jun 30, 2022 | -2.49 Mn |
| Mar 31, 2022 | -1.97 Mn |
| Nov 30, 2021 | -2.55 Mn |
| Aug 31, 2021 | -3.78 Mn |
| May 31, 2021 | -2.33 Mn |
| Feb 28, 2021 | -2.02 Mn |